These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35481358)

  • 21. In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses.
    Guo Y; Wang SZ; Zhang X; Jia HR; Zhu YX; Zhang X; Gao G; Jiang YW; Li C; Chen X; Wu SY; Liu Y; Wu FG
    Nat Commun; 2022 Nov; 13(1):6534. PubMed ID: 36319625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized approaches to active immunotherapy in cancer.
    Ophir E; Bobisse S; Coukos G; Harari A; Kandalaft LE
    Biochim Biophys Acta; 2016 Jan; 1865(1):72-82. PubMed ID: 26241169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
    Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
    Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
    ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.
    Kajihara M; Takakura K; Ohkusa T; Koido S
    Immunotherapy; 2015; 7(10):1111-22. PubMed ID: 26507578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor.
    Wang C; Huang X; Wu Y; Wang J; Li F; Guo G
    Int J Biol Sci; 2020; 16(4):633-643. PubMed ID: 32025211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
    Flores I; Hevia D; Tittarelli A; Soto D; Rojas-Sepúlveda D; Pereda C; Tempio F; Fuentes C; Falcón-Beas C; Gatica J; Falcón-Beas F; Galindo M; Salazar-Onfray F; González FE; López MN
    J Immunol Res; 2019; 2019():9631515. PubMed ID: 31886313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
    Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
    Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies.
    Hashemi F; Razmi M; Tajik F; Zöller M; Dehghan Manshadi M; Mahdavinezhad F; Tiyuri A; Ghods R; Madjd Z
    Stem Cells; 2023 Mar; 41(3):207-232. PubMed ID: 36573273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the efficacy of peptide vaccines in cancer immunotherapy.
    Zahedipour F; Jamialahmadi K; Zamani P; Reza Jaafari M
    Int Immunopharmacol; 2023 Oct; 123():110721. PubMed ID: 37543011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.
    Anticoli S; Aricò E; Arenaccio C; Manfredi F; Chiozzini C; Olivetta E; Ferrantelli F; Lattanzi L; D'Urso MT; Proietti E; Federico M
    J Mol Med (Berl); 2018 Feb; 96(2):211-221. PubMed ID: 29282521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.